Eledon 
Welcome,         Profile    Billing    Logout  
 2 Products   5 Diseases   2 Products   5 Trials   129 News 


12»
  • ||||||||||  galeterone (TOK-001) / Eledon
    Journal:  Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation. (Pubmed Central) -  Jul 28, 2024   
    Sensitivity was independent of androgen status and the Fluva-GAL combination significantly impeded CRPC tumor xenograft growth. By identifying cholesterol-mimetic drugs that inhibit SREBP2 activation upon statin treatment, we provide a potent "one-two punch" against CRPC progression and pave the way for innovative therapeutic strategies to combat additional diseases whose etiology is associated with SREBP2 dysregulation.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant (clinicaltrials.gov) -  Dec 11, 2023   
    P1/2,  N=24, Recruiting, 
    Inadequate IS and exogenous Ab infusion through blood and its products likely contributed. Phase classification: P1b --> P1/2 | N=12 --> 24 | Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses. (Pubmed Central) -  Oct 6, 2023   
    When treated with MLN8237 in combination with anti-PD-L1 antibody, the volumes of tumor were significantly reduced and accompanied by increasing the infiltration of CD3+ and CD8+ T cells in colorectal cancer xenograft tumor model. Our data demonstrated that MLN8237 improved the effect of immunology-related therapy on tumor cells by interacting with anti-PD-L1 antibody, which contributed to producing creative sparks for exploring the possible solutions to overcoming drug resistance to tumor targeted therapy.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Journal:  The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. (Pubmed Central) -  Sep 3, 2023   
    Furthermore, AT-1501-based regimens after islet transplant resulted in higher C-peptide, greater appetite leading to weight gain, and reduced occurrence of cytomegalovirus reactivation compared with conventional immunosuppression. These data support AT-1501 as a safe and effective agent to promote both islet and kidney allograft survival and function in nonhuman primate models, warranting further testing in clinical trials.
  • ||||||||||  galeterone (TOK-001) / Eledon
    PK/PD data, Preclinical, Journal:  Murine Toxicology and Pharmacokinetics of Lead Next Generation Galeterone Analog, VNPP433-3?. (Pubmed Central) -  Mar 11, 2023   
    is clearly not zero. Clearly, these toxicology and pharmacokinetics parameters pave the way for understanding the anticancer pharmacological actions and provide a meaningful basis for further preclinical development and eventual clinical development.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Trial completion date, Trial primary completion date:  Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant (clinicaltrials.gov) -  Jan 20, 2023   
    P1b,  N=12, Recruiting, 
    A correlation was found between in vitro assays and the score obtained from the molecular docking study. Trial completion date: Oct 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> Jul 2024
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Trial withdrawal, Immunomodulating:  Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation (clinicaltrials.gov) -  Aug 10, 2022   
    P2,  N=0, Withdrawn, 
    Therefore, VNPP433-3β exerts its antitumor effect by imposing 1) transcriptional regulation of AR and AR-responsive oncogenes 2) translational regulation by disrupting mRNA-5'cap-dependent translation initiation, 3) reducing AR half-life through enhanced proteasomal degradation in vitro and AR-overexpressing tumor xenografts in vivo. Recruiting --> Withdrawn
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Trial completion:  Multiple Doses of AT-1501-A201 in Adults With ALS (clinicaltrials.gov) -  Jul 14, 2022   
    P2a,  N=54, Completed, 
    Recruiting --> Withdrawn Active, not recruiting --> Completed
  • ||||||||||  galeterone (TOK-001) / Eledon
    Journal:  Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3β. (Pubmed Central) -  Jul 9, 2022   
    The structure of the target product (2, VNPP433-3β) was established by NMR spectroscopy, mass spectrometry and elemental analysis. Gal and VNPP433-3β exhibit more potent antiproliferative activities against CWR22Rv1 human prostate cancer cells compared to clinical drugs, Abiraterone and Enzalutamide.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Enrollment open:  Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) (clinicaltrials.gov) -  May 20, 2022   
    P2a,  N=42, Recruiting, 
    Transcriptome analyses by RNA-seq, Ingenuity Pathway Analysis, and Gene Set Enrichment Analysis demonstrate that VNPP433-3β inhibits transcription of several genes and functional pathways critical to the prostate CSCs thereby inhibiting CSCs in PCa besides targeting the bulk of the tumor. Not yet recruiting --> Recruiting
  • ||||||||||  GSK461364 / GSK, galeterone (TOK-001) / Eledon
    Journal:  Recent advancements on Benzimidazole: A versatile scaffold in medicinal chemistry. (Pubmed Central) -  Apr 7, 2022   
    A number of benzimidazoles such as bendamustine, pantoprazole have been approved for the treatment of various illnesses whereas galeterone and GSK461364 are in clinical trials. The present review article gives an overview about the different biological activities exhibited by the benzimidazole derivatives as well as different methods used for the synthesis of benzimidazole derivatives for the past ten years.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Enrollment open:  Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant (clinicaltrials.gov) -  Mar 16, 2022   
    P1b,  N=12, Recruiting, 
    The present review article gives an overview about the different biological activities exhibited by the benzimidazole derivatives as well as different methods used for the synthesis of benzimidazole derivatives for the past ten years. Not yet recruiting --> Recruiting
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Enrollment closed:  Multiple Doses of AT-1501-A201 in Adults With ALS (clinicaltrials.gov) -  Jan 10, 2022   
    P2a,  N=54, Active, not recruiting, 
    Initiation date: Nov 2021 --> Feb 2022 Recruiting --> Active, not recruiting
  • ||||||||||  abiraterone acetate / Generic mfg.
    Journal:  Novel nitrogen containing steroid derivatives for prostate cancer treatment. (Pubmed Central) -  Jan 7, 2022   
    It covers last decade of literature with highlights on the structure of new steroid compounds exhibiting significant activity in prostate cancer cells and possessing pharmacological potency. New derivatives of known anti-prostate cancer agents: abiraterone and galeterone, new derivatives of androstane and pregnane modified with nitrogen containing heterocycles, and some related steroid derived compounds are discussed in the review.
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Enrollment change, Immunomodulating:  Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation (clinicaltrials.gov) -  Sep 10, 2021   
    P2,  N=6, Recruiting, 
    Further preclinical and clinical evaluations of the lead compound Morusflavone are required to evaluate whether it can serve as a potential inhibitor of CYP17A1, which will be a new hope for prostate cancer treatment. N=12 --> 6
  • ||||||||||  tegoprubart (AT-1501) / Eledon
    Trial completion date, Trial primary completion date:  Multiple Doses of AT-1501-A201 in Adults With ALS (clinicaltrials.gov) -  Aug 18, 2021   
    P2a,  N=54, Recruiting, 
    N=12 --> 6 Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Sep 2021 --> Mar 2022
  • ||||||||||  galeterone (TOK-001) / Eledon
    Journal:  Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin. (Pubmed Central) -  Jun 24, 2021   
    Rescue studies demonstrated that both MNK/eIF4E and β-catenin were responsible for anti-breast cancer activity of galeterone. Our study provides pre-clinical evidence to initialize clinical trials for breast cancer using galeterone in combination with chemotherapy.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Enbrel (etanercept) / Pfizer, Amgen, AT-1501 / Eledon
    [VIRTUAL] AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates () -  May 18, 2021 - Abstract #ATC2021ATC_2362;    
    The other 4 groups incorporated T cell depletion with thymoglobulin (Thy; 5 peri-transplant doses at 5 mg/kg each), with a standard of care (SOC) group also receiving FK506 and rapamycin (target trough levels 8-12 and 4-6 ng/ml, respectively) plus Enbrel (0.8 mg/kg IV on POD 0 and 0.4 mg/kg SC on POD 3, 7, 10)... AT-1501 appears to be a safe and effective agent to promote islet engraftment and long-term survival and a promising tool for tolerance induction strategies.